U.S. Markets closed

FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

BALERNA, Switzerland, Dec. 4, 2019 /PRNewswire/ -- APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of Epidermolysis Bullosa ("EB").

APR Logo (PRNewsfoto/APR Applied Pharma Research s.a.)

APR-TD011 is a hypotonic acid-oxidizing solution containing hypochlorous acid in a sprayable form for topical application, specifically developed for EB. Thanks to its unique physico-chemical profile, APR-TD011 could be able to prevent or reduce infections as well as inflammation through modulation of the wound microenvironment, thus accelerating the physiological wound healing.

"The granting of Orphan Drug Designation in the US highlights the significant need for a drug that could improve the treatment of EB, a debilitating disease that affects the life of half a million people in the US. We believe that APR-TD011 holds great promises for EB patients and their families and the Orphan status will help APR to find expedited pathways to fruition," said Paolo Galfetti, CEO of APR. "This designation is also an important milestone and step forward in APR's evolution as we advance our pipeline targeting rare diseases."

EB market is estimated to range between $1.0 - 1.3 billion worldwide. EB imposes a major burden for global health care: the cost of treatment of a severely affected patients in the United States can exceed $300,000 per year, whereas wound care supplies for those with Dystrophic EB could require more than $10,000 per month.

The Orphan Drug Designation program provides incentives and support for the development of drugs for patients with rare diseases, specifically to drugs that are intended for the treatment of diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation provides certain benefits, including seven years of market exclusivity upon regulatory approval for the designated indication, exemption from FDA application user fees, FDA assistance in clinical trial design as well as tax credits (up to 25%) for qualified clinical trial expenses.

About APR-TD011

APR-TD011 is a hypotonic acidic oxidizing solution, containing hypochlorous acid, obtained through the company patented nanotechnology platform, Tehclo.

The solution is featured by an exclusive combination of three physico-chemical properties - highly pure HClO, hypotonic low pH and high ORP, which are believed to support a faster physiological healing of EB wounds by creating a favourable wound microenvironment. In particular, hypochlorous acid is well known as a broad-spectrum, fast acting antimicrobial agent, which reinforced by low pH and high ORP contributes to prevent and treat skin infections. APR-TD011 could also reduce inflammation by inhibiting the NF-kB pro-inflammatory pathway and by inactivating the Matrix metalloproteases, known to play a key role in the inflammatory process of wounds. APR-TD011 could reasonably ameliorate the quality of life of EB patients by supporting faster wound healing and by reducing itching and pain, linked to infections and inflammation. Available in an easy-to-use spray formulation, the solution allows wounds to be treated while avoiding skin contact and cross-contamination risk.

For more information please visit: https://www.apr.ch/apr-pharma-products/medical-prescription/apr-td011-epidermolysis-bullosa/.

About Epidermolysis Bullosa

Epidermolysis Bullosa (EB) is a group of rare, genetic, life-threatening connective tissue disorders characterized by skin blistering throughout the body as well as severe impact to internal organs. There are many genetic variations of EB with common symptom of fragile skin that blisters and tears. It is estimated that EB affects 1 out of 20,000 births and approximately half a million patients in the US with limited life expectancy.

EB is always painful, often pervasive and debilitating: itching, pain and scars reduce significantly the quality of life while persistent skin inflammation and infections are correlated to tumor incidence and early death. No approved treatments or cure are available. The standard of care is currently supportive treatments such as pain and wound management in order to prevent infections and sustain wound healing for the entire life. Wound care management remains a complex procedure affecting daily EB patients and caregivers. The goal is to obtain a faster and physiological healing of the wounds, avoiding or limiting infections (with the consequent use of antibiotics), as well as wounds chronicization.

About APR Applied Pharma Research s.a.

APR is a Swiss independent pharma company focused on development and commercialization of innovative, research-driven products designed to address unmet needs in niche and rare therapeutic areas. APR combines pharmaceutical development expertise with proprietary drug delivery technologies to develop solutions that meaningfully improve the lives of people with rare diseases. A diverse and balanced portfolio of revenue-generating products in all major markets is complemented by a robust pipeline of innovative products at different stages of development for the treatment of recessive metabolic disorders, as well as rare dermatological and ocular diseases. Products are commercialized by APR with its sales and marketing teams in selected countries of Europe and by a growing network of commercial partners. For more information, please visit: https://www.apr.ch/.

Forward-looking statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "project", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contacts:
APR Applied Pharma Research s.a.:
Elisabetta Bianchi, Corporate Communication Manager
elisabetta.bianchi@apr.ch
+41-91-6957020

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-apr-applied-pharma-researchs-investigational-drug-for-the-treatment-of-epidermolysis-bullosa-300968565.html

SOURCE APR Applied Pharma Research s.a.

  • The Democratic Presidential Candidates Are Becoming Less Popular
    Politics
    FiveThirtyEight

    The Democratic Presidential Candidates Are Becoming Less Popular

    To that effect, Monmouth University and Quinnipiac University each released a poll this week that asked voters whether they had a favorable or unfavorable opinion of leading Democratic presidential candidates and President Trump, but what each pollster found was pretty different. The Quinnipiac poll found that Trump received the worst marks overall — a net favorability rating (favorable rating minus unfavorable rating) of -17. This figure is 10 percentage points below the lowest-rated Democratic contender, Sen. Elizabeth Warren, and 14 points worse than former Vice President Joe Biden, whose net favorability rating was -3.

  • Here’s the formula for paying no federal income taxes on $100,000 a year
    Business
    MarketWatch

    Here’s the formula for paying no federal income taxes on $100,000 a year

    The question of how much can we earn without paying federal income taxes is relatively easy to answer for most people. The standard deduction for a married couple is $24,400 in 2019 (if both are under 65 years old), and the top of the 0% capital-gains tax bracket is $78,750. With our daughter, we also qualify for the child tax credit ($2,000), so we could actually generate another $13,333 per year in dividends or capital gains, taxed at 15%.

  • Is Affimed NV (AFMD) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Affimed NV (AFMD) Going to Burn These Hedge Funds?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Affimed NV (NASDAQ:AFMD). Is Affimed NV (NASDAQ:AFMD) the right pick for your portfolio?

  • Hedge Funds Have Never Been Less Bullish On Southwestern Energy Company (SWN)
    Business
    Insider Monkey

    Hedge Funds Have Never Been Less Bullish On Southwestern Energy Company (SWN)

    How do we determine whether Southwestern Energy Company (NYSE:SWN) makes for a good investment at the moment? Southwestern Energy Company (NYSE:SWN) investors should pay attention to a decrease in hedge fund sentiment in recent months. SWN was in 14 hedge funds' portfolios at the end of September.

  • 5 Cheap Dividend Stocks With High Yields And Annual Increases
    Business
    InvestorPlace

    5 Cheap Dividend Stocks With High Yields And Annual Increases

    In addition, the dividend yields have to be higher than average. This is much higher than the S&P 500, with its dividend yield of 1.8%. The price-to-earnings ratio hurdle to make my list is 11 times or lower.

  • Is Fortuna Silver Mines Inc. (FSM) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Fortuna Silver Mines Inc. (FSM) Going to Burn These Hedge Funds?

    Hedge fund interest in Fortuna Silver Mines Inc. NYSE:FSM) shares was flat at the end of last quarter. This is usually a negative indicator.

  • Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks
    Business
    TipRanks

    Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks

    To watch Boyd's track record, click here) BP shares have received three recent Buy ratings, giving the stock a unanimous 'Strong Buy' from the analyst consensus. The average price target stands tall at $51.33 -- indicating a robust upside potential of 39%. See BP stock analysis on TipRanks) BP wasn't the only energy industry company that Soros was interested in.

  • Hedge Funds Have Never Been More Bullish On New York Mortgage Trust, Inc. (NYMT)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On New York Mortgage Trust, Inc. (NYMT)

    Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their portfolios in smaller cap stocks. In this article, we will take a closer look at hedge fund sentiment towards New York Mortgage Trust, Inc. (NASDAQ:NYMT). Overall, hedge fund sentiment was unchanged.

  • Biggest risks for financial markets in 2020
    Business
    Yahoo Finance Video

    Biggest risks for financial markets in 2020

    Stocks may be at record highs as the year winds down, but Wall Street is already issuing warnings about a host of threats to the markets in 2020. E-Valuator Funds CIO Kevin Miller joins the On the Move panel to discuss why a China trade agreement fallout and the Fed raising rates are top concerns for next year.

  • Do Hedge Funds Love Inovalon Holdings Inc (INOV)?
    Business
    Insider Monkey

    Do Hedge Funds Love Inovalon Holdings Inc (INOV)?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Should you consider Inovalon Holdings Inc (NASDAQ:INOV) for your portfolio? Inovalon Holdings Inc (NASDAQ:INOV) investors should pay attention to an increase in hedge fund interest of late.

  • Democrats threaten to boycott next debate over labor dispute
    Politics
    Associated Press

    Democrats threaten to boycott next debate over labor dispute

    All seven Democratic presidential candidates who qualified for next week's debate threatened on Friday to skip the event if an ongoing labor dispute forces them to cross picket lines on the campus hosting it. The Democratic National Committee said it is trying to come up with an "acceptable resolution” to the situation so the debate can proceed. A labor union called UNITE HERE Local 11 says it will picket as Loyola Marymount University hosts Thursday's sixth Democratic debate of the cycle, and Massachusetts Sen. Elizabeth Warren and Vermont Sen. Bernie Sanders responded by tweeting they wouldn't participate if that meant crossing it.

  • Mercedes Delays Electric Debut After Jaguar and Audi SUVs Flop
    Business
    Bloomberg

    Mercedes Delays Electric Debut After Jaguar and Audi SUVs Flop

    Daimler AG's luxury brand will start sales of the EQC crossover in 2021 rather than early next year. The world's top-seller of premium autos has touted the EQC and the series of battery-powered models it has planned under the EQ sub-brand as an answer both to Tesla and its traditional rivals. Jaguar has sold 2,418 I-Pace SUVs in the U.S. this year through November, while Audi has delivered 4,623 e-tron crossovers, according to InsideEVs.

  • World
    Bloomberg

    China Threatens Germany With Retaliation If Huawei 5G Is Banned

    China's ambassador threatened Germany with retaliation if it excludes Huawei Technologies Co. as a supplier of 5G wireless equipment, citing the millions of vehicles German carmakers sell in China. Resistance against Huawei is growing among lawmakers in Chancellor Angela Merkel's governing coalition, who have challenged her China policy with a bill that would impose a broad ban on “untrustworthy” 5G vendors. If Germany were to take a decision that leads to Huawei's exclusion from the German market, there will be consequences,” Ambassador Wu Ken said Saturday at a Handelsblatt event.

  • 3 Great Semiconductor Stocks to Invest In for 2020
    Business
    InvestorPlace

    3 Great Semiconductor Stocks to Invest In for 2020

    As InvestorPlace.com contributor Luke Lango pointed out, “Since early 2018, escalating trade tensions between the U.S. and China have weighed on global semiconductor demand and sales. But, those escalating trade tensions are now de-escalating, and should continue to de-escalate into 2020. As they do, semiconductor demand and sales will rebound.

  • Is It Worth Buying Costco Wholesale Corporation (NASDAQ:COST) For Its 0.9% Dividend Yield?
    Business
    Simply Wall St.

    Is It Worth Buying Costco Wholesale Corporation (NASDAQ:COST) For Its 0.9% Dividend Yield?

    Of the free cash flow it generated last year, Costco Wholesale paid out 31% as dividends, suggesting the dividend is affordable. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

  • Google Workers Rising Up After Employees Are Fired
    Business
    Bloomberg

    Google Workers Rising Up After Employees Are Fired

    Google fired four employees for what the technology giant said were violations of its data-security policies, escalating tension between management and activist workers at a company once revered for its open corporate culture. Rebecca Rivers, a former Google employee, and Bloomberg's Mark Bergen appear on "Bloomberg Technology."

  • Boeing loses battle to develop long-haul plane
    Business
    American City Business Journals

    Boeing loses battle to develop long-haul plane

    The Boeing Co. has lost out to rival Airbus in the bid to develop an aircraft that Australian flagship carrier Qantas aims to introduce on ultra-long-haul flights. The plane could be used on the Chicago-to-Brisbane route that Qantas will start flying on April 15. Qantas CEO Alan Joyce said of the carrier's choice of the Airbus model aircraft: “Airbus gives us the best possible combination of commercial terms, fuel efficiency, operating cost and customer experience.” Qantas' decision to go with a version of the Airbus A350-1000 comes after Boeing (NYSE: BA) has been in the public spotlight for months as multiple agencies have investigated the development of the troubled Boeing 737 MAX.

  • Bristol-Myers wins $752 million in U.S. patent case against Gilead
    Business
    Reuters

    Bristol-Myers wins $752 million in U.S. patent case against Gilead

    Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer. A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead's Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers' Juno Therapeutics division. The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

  • Hedge Funds Are Dumping NIO Limited (NIO)
    Business
    Insider Monkey

    Hedge Funds Are Dumping NIO Limited (NIO)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). NIO Limited (NYSE:NIO) was in 13 hedge funds' portfolios at the end of the third quarter of 2019. There were 14 hedge funds in our database with NIO holdings at the end of the previous quarter.

  • A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE
    Business
    Simply Wall St.

    A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE

    Today we'll evaluate Verizon Communications Inc. (NYSE:VZ) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. First up, we'll look at what ROCE is and how we calculate it.

  • Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ?

    Two of the most useful methods are hedge fund and insider trading activity. We have shown that, historically, those who follow the best picks of the best money managers can outpace the broader indices by a significant amount (see the details here). We leave no stone unturned when looking for the next great investment idea.

  • When Chevron leaves the region, so will most of its charitable giving
    Business
    American City Business Journals

    When Chevron leaves the region, so will most of its charitable giving

    The biggest was the $20 million Appalachian Partnership Initiative, a five-year program with community groups to build up STEM and workforce training initiatives. But Chevron and its employees have been monetary and time contributors for a host of other charitable initiatives, from the Pro Football Alumni charity golf tournament to more than 100 local schools and Intermediate Unit 1, and partnerships with the Carnegie Science Center, the Pittsburgh Pirates and the Children's Museum of Pittsburgh, among others. That legacy, and the active engagement of Chevron employees from the top down on volunteer work and board work, is going to be missed when the company exits Appalachia.

  • Business
    Reuters

    California governor rejects PG&E bankruptcy reorganization plan

    California Governor Gavin Newsom on Friday rejected a bankruptcy reorganization plan submitted by PG&E Corp, the state's largest investor-owned utility, saying its proposal fails to meet the requirements of a recently enacted wildfire law. The decision by Newsom, sent to PG&E in a letter, complicates the company's push to exit bankruptcy and provide billions of dollars to victims of devastating wildfires in 2017 and 2018 sparked by the utility's power lines. The embattled utility now has until Tuesday to further amend its plan to Newsom's satisfaction, but his criticism of the reorganization package as it was presented by PG&E a day earlier was sweeping.

  • Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy?

    Is Viking Therapeutics, Inc. NASDAQ:VKTX) ready to rally soon? Investors who are in the know are in a pessimistic mood.

  • Value of Amazon building shoots up 170 percent in eight years
    Business
    American City Business Journals

    Value of Amazon building shoots up 170 percent in eight years

    The tenant, Amazon, is the reason for the skyrocketing value of the 29-year-old building, which Amazon named Alexandria. This is the latest big commercial real estate sales this week as sellers stampede to avoid the Jan. 1 increase of the state real estate excise tax hike. A joint venture of Talon Private Capital of Seattle and Prudential Realty Group, bought the building in December 2011 from Regence BlueShield, which leased about a third of the tower.